Profiling the safety and tolerability of bisphosphonates

被引：22

作者：

Body, JJ

Diel, I

Bell, R

机构：

[1] Free Univ Brussels, Inst Jules Bordet, Dept Med, B-1000 Brussels, Belgium

[2] Inst Gynaecol Oncol, Ctr Comprehens Gynaecol, Mannheim, Germany

[3] Andrew Love Canc Ctr, Geelong, Vic, Australia

来源：

SEMINARS IN ONCOLOGY | 2004年 / 31卷 / 05期

关键词：

D O I：

10.1053/j.seminoncol.2004.07.030

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：73 / 78

页数：6

共 31 条

[1] Extended safety profile of oral clodronate after long-term use in primary breast cancer patients [J].

Atula, S ;

Powles, T ;

Paterson, A ;

McCloskey, E ;

Nevalainen, J ;

Kanis, J .

DRUG SAFETY, 2003, 26 (09) :661-671

[2]

Banerjee D, 2003, AM J KIDNEY DIS, V41

[3] Ibandronate: A clinical pharmacological and pharmacokinetic update [J].

Barrett, J ;

Worth, E ;

Bauss, F ;

Epstein, S .

JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (09) :951-965

[4] Renal safety of ibandronate in patients with bone metastases from breast cancer:: phase III trial results [J].

Bell, R. ;

Diel, I. J. ;

Body, J. ;

Bergstroem, B. .

EJC SUPPLEMENTS, 2004, 2 (03) :132-132

[5] Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies [J].

Body, JJ ;

Diel, IJ ;

Lichinitzer, M ;

Lazarev, A ;

Pecherstorfer, M ;

Bell, R ;

Tripathy, D ;

Bergstronn, B .

BRITISH JOURNAL OF CANCER, 2004, 90 (06) :1133-1137

[6] Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases [J].

Body, JJ ;

Diel, IJ ;

Lichinitser, MR ;

Kreuser, ED ;

Dornoff, W ;

Gorbunova, VA ;

Budde, M ;

Bergström, B .

ANNALS OF ONCOLOGY, 2003, 14 (09) :1399-1405

[7]

BODY JJ, 2004, P AN M AM SOC CLIN, V23, P60

[8]

BODY JJ, 2001, SEMIN ONCOL S, V11, P2849

[9]

CHANG JT, 2003, NEW ENGL J MED, V349, P1179

[10] Efficacy of zoledronic acid and pamidronate in breast cancer patients: A comparative analysis of Randomized phase III trials [J].

Coleman, RE .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (06) :S25-S31

← 1 2 3 4 →